Back to Agenda
Session 7: The Future of the Intercenter Collaboration at FDA
Session Chair(s)
John Weiner, JD
Associate Director for Policy, Office of Combination Products, OCPP, OC
FDA, United States
This session presents the forward-looking views of key FDA thought leaders about the future of innovative product development and how it may be supported by an evolving holistic approach characterized by collaboration across centers. Our panelists will discuss the vision for such collaboration, challenges in achieving it, and its potential benefits and impact on innovative therapies.
Speaker(s)
Speaker
William H. Maisel, MD, MPH
FDA , United States
Deputy Director for Science and Chief Scientist, Director, ODE (Acting), CDRH
Speaker
Thinh X. Nguyen
FDA, United States
Director, Office of Combination Products, OCPP
Speaker
Douglas C. Throckmorton, MD
FDA, United States
Deputy Center Director for Regulatory Programs CDER
Speaker
Sheryl L. Lard Whiteford, PhD
FDA, United States
Associate Director for Quality Assurance, OCD, CBER
Have an account?